Author + information
This clinical study aimed to investigate MPO (myeloperoxidase) activity that is a marker of inflammatory and oxidative stress, is weather or not a marker to determine stable CAD (coronary artery disease) in MetS (metabolic syndrome) and to show the association between MPO activity and other inflammatory biomarkers (malondialdehyde (MDA),CRP, WBC, Fibrinogen).
93 non-diabetic Mets subjects who underwent coronary angiography were enrolled in this study. Patient groups included 58 subjects (47 male, 11 female; mean age 59.6±11.2) who were diagnosed coronary artery disease and control group included 35 subjects (11 male, 24 female; mean age 50.7±8.8) without coronary artery disease. No patient have a recent history of an acute infection or an inflammatory disease.
In our study MPO activity, hsCRP, WBC and fibrinogen levels showed no significant differences between CAD+ MetS group and non-CAD+MetS group (p>0,05). We found that MDA levels in MetS CAD groups were significantly higher than non-CAD Mets groups (p<0,05) (Table 1).
Our results show that MPO activity, hsCRP, WBC and fibrinogen levels were not seem to be a biomarker for stable CAD in MetS, independently component of Mets. However this study suggests that MDA level will may be a biomarker for CAD in MetS. MDA is one of frequently used indicator of lipid peroxidation. MPA may be a potential biomarker for oxidative stress and a predictor of KAH in MetS groups.